^
Association details:
| Biomarker: | BRAF Y472C |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | dasatinib (c-KIT inhibitor, Bcr-abl tyrosine kinase inhibitor, Src kinase inhibitor, EphA2 receptor antagonist, PDGFR β antagonist) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Kinase Impaired BRAF Mutations Confer Lung Cancer Sensitivity to Dasatinib
Excerpt:
We identified a patient with stage IV NSCLC with long term disease control by single-agent dasatinib therapy alone. His tumor harbored a kinase inactivating Y472CBRAF mutation that was likely responsible for its unusual sensitivity to dasatinib.
DOI:
10.1126/scitranslmed.3003513
